If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 3 of 3

A Phase 1, Open-Label, Multicenter, First-in-Human Trial of DS3610A in Participants With Advanced Solid Tumors

Objective
A Phase 1 Study of DS3610A in participants with advance solid tumor cancer.
Protocol No
DAIICHI-DS3610-071
Categories
Cancer, Early Phase/Multiple Disease Site Cancers, Lip, Oral Cavity and Pharynx, Other Skin, Other Respiratory, Colorectal, Pancreas/Liver, Skin Cancers, Other Gynecologic, Other Gastrointestinal, Ovary, Prostate, Thoracic Cancers, Gastrointestinal Cancers, Sarcoma, Uterine, Kidney, Gynecologic Cancers, Breast Cancers, Eye/Orbital Cancers, Head and Neck Cancers, Other Urologic, Endocrine Cancers, Prostate and Urologic Cancers

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Subjects with KRAS G12C Mutant Advanced Solid Tumors

Objective
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
Categories
Cancer, Kidney, Other Skin, Thoracic Cancers, Sarcoma, Gastrointestinal Cancers, Cervix, Prostate and Urologic Cancers, Other Gynecologic, Breast Cancers, Ovary, Gynecologic Cancers, Head and Neck Cancers, Early Phase/Multiple Disease Site Cancers, Endocrine Cancers, Melanoma, Skin, Eye/Orbital Cancers, Skin Cancers

A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors

Objective
A Phase 1 study of BG-75098 alone and in combination with BGB-43395 and/or Fulvestrant in Patients with Advanced Solid Tumors.
Protocol No
BEONE-BG-75098-101
Categories
Cancer, Early Phase/Multiple Disease Site Cancers, Other Respiratory, Other Skin, Pancreas/Liver, Prostate, Other Gynecologic, Colorectal, Skin Cancers, Gynecologic Cancers, Bladder, Lung, Other Gastrointestinal, Esophagus, Breast Cancers, Esophagus, Gastrointestinal Cancers, Prostate and Urologic Cancers, Sarcoma, Lip, Oral Cavity and Pharynx, Thoracic Cancers, Head and Neck Cancers